Navigation Links
Gene Screen May Predict Colon Cancer's Return
Date:5/14/2009

That knowledge could guide important treatment decisions, experts say

THURSDAY, May 14 (HealthDay News) -- The first genomic test aimed at predicting colon cancer recurrence may help individualize treatment for patients, leading to less toxic and more targeted therapy choices, scientists say.

The Oncotype DX test differentiated which patients with stage II colon cancer were more likely to have a recurrence and which were not. According to the research team, those with lower odds of recurrence might be able to forgo sometimes toxic and costly chemotherapy and stick to surgery alone.

The study is to be presented at the American Society of Clinical Oncology (ASCO) annual meeting, which starts later this month in Florida. The U.K. researchers described their findings Thursday in a special ASCO preview news conference.

The new gene test was not able to show whether or not chemotherapy would actually benefit the higher-risk group, the researchers said.

Still, "we think this will be a clinically useful tool when coming to select which patients will receive chemotherapy," said study lead author Dr. David Kerr, a professor of cancer medicine at the University of Oxford.

The test is very similar to the Oncotype DX test that is already available to stratify breast cancer patients by risk, added Dr. Richard L. Schilsky, president of ASCO and professor of medicine at the University of Chicago. In fact, the new colon cancer test will likely be commercialized by the same company that markets the breast cancer test, Genomic Health, he predicted. That company funded the new study.

The study authors believe the new test, which is not quite as strong a predictor as the existing breast cancer test, will be available for use in hospitals by 2010.

"One of the major challenges facing us as oncologists is selecting the right patients for the right drugs at the right time. That's what this study is all about," Kerr said.

Most individuals diagnosed with relatively early, stage II colon cancer (representing 25 to 30 percent of all cases) can be cured with surgery alone. A small minority benefit from added chemo.

But, Kerr said, "there's no clear consensus on how to select patients" who might gain from this additional chemotherapy, and weed out those who would not.

The research team started out by analyzing almost 800 genes from almost 1,900 colon cancer patients. They then tested an initial, promising gene signature in about 1,500 patients. Half of these individuals received chemo and half did not.

The presence of certain genes was able to predict those with a higher risk of recurrence and those with a lower risk, the team found.

"A seven-gene signature for the first time ever gives a significant prognostic recurrence score," Kerr said. "This allows us to define a population of patients at low risk of recurrence -- about a 10 percent chance of the cancer coming back [in three years] -- in whom I would counsel that chemotherapy would be of very little value indeed."

For the other group, recurrence rates closer to 20 or 25 percent at three years may indicate a benefit to getting chemo, he said.

Doctors already look at "T-stage" of a tumor (is it locally advanced?, etc.) as well as "mismatch repair," which refers to a gene repair mechanism, to predict recurrence. However, according to Kerr, a large group of patients would benefit from this new tool that would not benefit from the two older screens.

"The new tool is an independent important variable," Kerr said. "There would be 70 percent of patients in whom T-stage and mismatch will not be informative and we think that, in this group, the new tool will provide a useful addendum to the clinical decision-making process."

More information

There's more on colorectal cancer at the U.S. National Cancer Institute.



SOURCES: May 14, 2009, American Society of Clinical Oncology press teleconference with David Kerr, M.D., D.Sc., professor, cancer medicine, University of Oxford, and Richard L. Schilsky, M.D., president, ASCO and professor, medicine at the University of Chicago; study abstract


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Proposes New Rules for Sunscreens
2. Frequent Prostate Screens Fail to Improve Aggressive Cancer Diagnoses
3. FDA Approves New Roche West Nile Virus Blood Screening Test
4. Physician Skin Care Specialist Says Proposed New Rules for Sunscreen Products Will Better Protect the Public
5. New lung cancer guidelines oppose general CT screening
6. New Lung Cancer Guidelines Oppose General CT Screening
7. Lung Cancer Alliance Stands Behind CT Screening for Lung Cancer
8. Prostate Cancer Awareness Week to Screen Thousands
9. Screening Proposed for Childhood Cholesterol Levels
10. A new technology for cancer screening listens for the signs of cancer
11. Study Questions Genetic Screening for Treatable Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene Screen May Predict Colon Cancer's Return
(Date:3/27/2017)... CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still in shock ... the best days I’ve had in a long time,” she said. , She thinks the ... of money that I never thought I would have to help my students.” , The ...
(Date:3/27/2017)... Switzerland (PRWEB) , ... March 27, 2017 , ... ... food industry. Conventional sodium testing methods are complicated and require expert user knowledge. ... a new analytical method dedicated to the simplified, yet highly accurate, determination of ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... GTEC Orange facility from 8:00am-10:00am on Monday, April 3rd to commemorate the two-year ... be an opportunity for area-residents to celebrate two great years while also familiarizing ...
(Date:3/27/2017)... ... 2017 , ... Harris Communications, Inc., a leading provider of assistive technology ... the Deaf Seniors of America Conference, April 4-7 at the Hotel Westin Galleria in ... friendly staff from Harris Communications and to try out the newest assistive devices available ...
(Date:3/25/2017)... ... March 25, 2017 , ... Norland at Swissray is pleased to announce the ... subjects. The ELITE DXA has an active scan window, which is more than double ... fit in the scan area could not undergo an accurate total body bone density or ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017  Sophiris Bio Inc. (NASDAQ: ... clinical late-stage biopharmaceutical company developing topsalysin (PRX302) for ... reported fourth quarter and full year 2016 financial ... Key Corporate Highlights: Advanced Topsalysin ... During 2016, the Company reported successful results with ...
(Date:3/27/2017)... , March 27, 2017 BioLineRx ... and immunology, announced today that AGI-134, an immunotherapy for the ... of Agalimmune Ltd., will be featured at the upcoming ... Washington, DC to be held on ... ...
(Date:3/27/2017)... , March 27, 2017 The staggering cost ... wealthiest countries have access to the latest treatment options ... the US, many patients have inadequate or no health ... skip therapy altogether. Access to modern cancer treatment is ... countries. The mission statements of pharmaceutical ...
Breaking Medicine Technology: